# Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)

> **NCT02469415** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Pacritinib
- **DRUG:** 5-azacitidine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT02469415
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-30
- **Primary completion:** 2017-06-03
- **Final completion:** 2017-06-03
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** FDA Clinical Hold
- **Last updated:** 2018-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02469415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02469415, "Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02469415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*